Paul Tudor Jones Summit Therapeutics Inc. Transaction History
Tudor Investment Corp Et Al
- $26.8 Billion
- Q3 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 16,400 shares of SMMT stock, worth $307,992. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,400Holding current value
$307,992% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding SMMT
# of Institutions
192Shares Held
75.8MCall Options Held
2.01MPut Options Held
2.84M-
Baker Bros. Advisors LP New York, NY24.4MShares$459 Million5.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$206 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$148 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.44MShares$102 Million0.01% of portfolio
-
State Street Corp Boston, MA3.47MShares$65.1 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.78B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...